Within the third quarter of 2021, European life sciences corporations raised a complete of EUR 2.2bn in enterprise capital funding. Though the efficiency is sort of the identical as in the identical quarter final 12 months, the gathered funding quantity in 2021 elevated by 65% in comparison with the primary three quarters of 2020. As well as, the gathered quantity of 2021 already exceeds the whole funding quantity of 2020 by 23%.
In 2021 to this point, the biggest transaction has been the Sequence D enterprise funding of UK-based CMR Surgical within the quantity of EUR 497m.